Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 8,763 Shares

Boston Scientific Corporation (NYSE:BSX) SVP David A. Pierce sold 8,763 shares of Boston Scientific stock in a transaction dated Thursday, January 11th. The shares were sold at an average price of $27.74, for a total value of $243,085.62. Following the sale, the senior vice president now owns 24,201 shares of the company’s stock, valued at $671,335.74. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Shares of Boston Scientific Corporation (BSX) traded down $0.09 during mid-day trading on Thursday, hitting $27.43. The company had a trading volume of 8,963,380 shares, compared to its average volume of 12,170,000. The company has a debt-to-equity ratio of 0.58, a current ratio of 0.72 and a quick ratio of 0.50. Boston Scientific Corporation has a 1-year low of $22.94 and a 1-year high of $29.93. The company has a market cap of $37,670.00, a P/E ratio of 44.97, a price-to-earnings-growth ratio of 1.82 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share for the quarter, meeting the Zacks’ consensus estimate of $0.31. The business had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.21 billion. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The firm’s revenue was up 5.6% compared to the same quarter last year. During the same period last year, the business earned $0.27 EPS. sell-side analysts predict that Boston Scientific Corporation will post 1.25 earnings per share for the current fiscal year.

Several equities research analysts have recently issued reports on the company. Canaccord Genuity assumed coverage on Boston Scientific in a report on Tuesday, October 24th. They set a “buy” rating and a $36.00 price target for the company. Zacks Investment Research upgraded Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price target for the company in a report on Friday, October 20th. Needham & Company LLC reiterated a “buy” rating and set a $32.00 price target on shares of Boston Scientific in a report on Tuesday, October 3rd. BMO Capital Markets reissued a “buy” rating and issued a $30.00 price objective on shares of Boston Scientific in a research note on Friday, October 13th. Finally, SunTrust Banks reissued a “buy” rating and issued a $34.00 price objective on shares of Boston Scientific in a research note on Monday, October 2nd. Two research analysts have rated the stock with a sell rating, four have assigned a hold rating, twelve have issued a buy rating and two have issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus target price of $31.00.

A number of hedge funds and other institutional investors have recently modified their holdings of BSX. Janus Henderson Group PLC increased its position in Boston Scientific by 22,491.6% in the 2nd quarter. Janus Henderson Group PLC now owns 38,862,599 shares of the medical equipment provider’s stock worth $1,077,270,000 after buying an additional 38,690,577 shares during the period. BlackRock Inc. increased its position in Boston Scientific by 4.6% in the 2nd quarter. BlackRock Inc. now owns 100,184,511 shares of the medical equipment provider’s stock worth $2,777,113,000 after buying an additional 4,439,966 shares during the period. Prudential Financial Inc. increased its position in Boston Scientific by 149.1% in the 3rd quarter. Prudential Financial Inc. now owns 4,762,674 shares of the medical equipment provider’s stock worth $138,928,000 after buying an additional 2,850,630 shares during the period. Vanguard Group Inc. increased its position in Boston Scientific by 2.8% in the 2nd quarter. Vanguard Group Inc. now owns 93,657,300 shares of the medical equipment provider’s stock worth $2,596,181,000 after buying an additional 2,522,556 shares during the period. Finally, American Century Companies Inc. increased its position in Boston Scientific by 28.9% in the 3rd quarter. American Century Companies Inc. now owns 10,496,489 shares of the medical equipment provider’s stock worth $306,183,000 after buying an additional 2,352,297 shares during the period. 90.36% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: “Boston Scientific Corporation (BSX) SVP David A. Pierce Sells 8,763 Shares” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/11/boston-scientific-corporation-bsx-svp-david-a-pierce-sells-8763-shares.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply